From Blood Sample to Breakthrough: How Reliance’s New Patent Could Transform Early Cancer Diagnosis in India

Cancer remains one of the most challenging health concerns worldwide, especially in India, where thousands of new cases are reported every day. One of the biggest reasons for poor survival rates is that many cancers are diagnosed only after they have reached advanced stages. A recent breakthrough by Reliance Industries’ subsidiary, Strand Life Sciences, may help change that reality.

Strand Life Sciences has secured an Indian patent for an advanced blood-based cancer detection platform that uses cutting-edge genomics, artificial intelligence (AI), and machine learning to identify cancer at an early stage. This innovation represents a significant step toward making cancer screening more accurate, accessible, and scalable across India.

A New Era of Blood-Based Cancer Detection

Unlike traditional diagnostic methods that often require tissue biopsies or invasive procedures, the newly patented technology works with a simple blood sample. The platform analyzes cell-free DNA (cfDNA)—tiny DNA fragments released into the bloodstream by cells, including cancer cells.

The system combines several advanced technologies, including:

• High-quality genome sequencing
• Methylation analysis
• Fragmentomics
• Artificial intelligence and machine learning

Together, these technologies help detect the presence of cancer while also predicting the tissue where the cancer may have originated. This integrated approach has the potential to improve both the speed and accuracy of diagnosis.

The Patent’s Biggest Innovation

The most notable feature covered under the newly granted patent is an innovative method for deriving DNA methylation patterns through genome sequencing with minimal failure rates.

DNA methylation refers to natural chemical modifications on DNA that often change when cancer develops. Detecting these subtle changes accurately is critical because they frequently appear before obvious symptoms or tumors become detectable through conventional methods.

By reducing sequencing failures and improving the quality of methylation data, the technology significantly enhances the sensitivity of early cancer detection, allowing doctors to identify disease at an earlier and potentially more treatable stage.

Why Early Detection Matters

According to healthcare estimates, India records approximately 1.5 million new cancer cases every year. Unfortunately, many patients receive their diagnosis only after the disease has progressed significantly.

Late diagnosis often results in:

• More complicated treatments
• Higher medical expenses
• Lower survival rates
• Reduced quality of life

Early detection dramatically increases treatment success and offers patients better clinical outcomes. However, current screening programs cover only a limited number of cancer types and are difficult to expand nationwide.

Blood-based screening technologies like this could bridge that gap by making large-scale testing more practical and affordable.

AI and Genomics Working Together

Artificial intelligence plays a vital role in this platform. Instead of relying solely on laboratory observations, machine learning algorithms analyze massive genomic datasets to identify cancer-specific biological patterns that might otherwise go unnoticed.

The integration of AI enables:

• Faster interpretation of genomic data
• Higher diagnostic accuracy
• Prediction of tissue of origin
• Continuous improvement as more clinical data becomes available

This combination of genomics and AI represents one of the fastest-growing areas in precision medicine.

Supporting Precision Oncology

The patent further strengthens Strand Life Sciences’ growing portfolio in liquid biopsy and precision oncology.

Liquid biopsy is emerging as one of the most promising technologies in cancer care because it enables physicians to monitor cancer using blood samples instead of repeated tissue biopsies.

This approach may eventually support:

• Early cancer screening
• Monitoring treatment effectiveness
• Detecting recurrence
• Personalized treatment planning

Such innovations align with the global shift toward minimally invasive and patient-friendly healthcare solutions.

Looking Ahead

As genome sequencing continues to become more affordable, technologies like this patented platform could make nationwide cancer screening increasingly feasible without requiring major healthcare infrastructure expansion.

For India, where cancer incidence continues to rise, scalable innovations that combine biotechnology, artificial intelligence, and genomic science may significantly improve public health outcomes over the coming years.

Reliance-backed Strand Life Sciences’ latest patent is more than an intellectual property milestone—it reflects the growing role of Indian innovation in developing advanced diagnostic technologies capable of improving early cancer detection and supporting better patient care.